Evidence map›Paper›PMID 42515769›Full record

ArticlePharmaceuticals (Basel, Switzerland)2026

A Bioequivalence Study Comparing Two Pomalidomide Hard Capsule Formulations in Healthy Chilean Subjects.

Marcelo Gomes Davanço, Thaís Pereira Vespasiano, Jessé Moisan, Oscar Gonzalez, Milesa Sarmiento, Mélanie Groleau

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marcelo Gomes DavançoMedical & Clinical Affairs Department, United Medical Ltd. (A Knight Therapeutics Company), Sao Paulo 04085-001, SP, Brazil.ORCID 0000-0002-1684-6591
Thaís Pereira VespasianoMedical & Clinical Affairs Department, United Medical Ltd. (A Knight Therapeutics Company), Sao Paulo 04085-001, SP, Brazil.
Jessé MoisanMedical & Clinical Affairs Department, Knight Therapeutics Inc., Montreal, QC H4M 2P2, Canada.ORCID 0000-0002-2695-094X
Oscar GonzalezR&D Department, Laboratorio LKM S.A. (A Knight Therapeutics Company), Buenos Aires C1179, Argentina.
Milesa SarmientoR&D Department, Laboratorio LKM S.A. (A Knight Therapeutics Company), Buenos Aires C1179, Argentina.
Mélanie GroleauMedical & Clinical Affairs Department, Knight Therapeutics Inc., Montreal, QC H4M 2P2, Canada.

Funding

Laboratorio LKM Chile SpA (a Knight Therapeutics company). Project n. PRO-BEQ-PMD-002
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bioavailabilitybioequivalencegenericsmultiple myelomapharmacokineticspomalidomide

Identifiers

PMID42515769
PMCPMC13414755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.